Essentially, cereblon and its target proteins can change shape to form a complex with the cereblon, the target, and the ...

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking ...

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, has made significant advancements in drug discovery as highlighted in a cover article published in Science. The research ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue ...

Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion. The agreement is for Monte Rosa's MRT-6160 drug and other ...

Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with a potential $2.1 billion in milestone payments.

Monte Rosa Therapeutics is at it again, banking $95 million just six months after reeling in a $96 million series B. The funds will propel the company’s lead protein-degrading program into the ...

Monte Rosa Therapeutics is capping off a fundraising spree with a $222.3 million IPO to get two of its “molecular glue” treatments into the clinic and advance its other discovery-stage programs.

Shares of Monte Rosa Therapeutics (GLUE) have gained 22.5% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term ...

Monte Rosa previously raised a Series A funding round in May of this year, worth $32.5 million. Versant Ventures led the round and launched Monte Rosa from its Ridgeline discovery engine based in ...

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...